Alx Oncology Holdings (ALXO) Income towards Parent Company (2019 - 2026)
Alx Oncology Holdings' Income towards Parent Company history spans 5 years, with the latest figure at $91.1 million for Q4 2023.
- On a quarterly basis, Income towards Parent Company rose 28.49% to $91.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$24.7 million, a 12.83% decrease, with the full-year FY2025 number at -$497000.0, up 99.63% from a year prior.
- Income towards Parent Company hit $91.1 million in Q4 2023 for Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for ALXO hit a ceiling of $91.1 million in Q4 2023 and a floor of -$51.0 million in Q3 2023.
- Historically, Income towards Parent Company has averaged -$6.5 million across 5 years, with a median of -$11.3 million in 2020.
- Biggest five-year swings in Income towards Parent Company: tumbled 234.46% in 2020 and later soared 3265.38% in 2022.
- Tracing ALXO's Income towards Parent Company over 5 years: stood at -$7.8 million in 2019, then soared by 322.41% to $17.3 million in 2020, then tumbled by 87.8% to $2.1 million in 2021, then soared by 3265.38% to $70.9 million in 2022, then grew by 28.49% to $91.1 million in 2023.
- Business Quant data shows Income towards Parent Company for ALXO at $91.1 million in Q4 2023, -$51.0 million in Q3 2023, and -$34.5 million in Q2 2023.